The Medicines Co., of Parsippany, N.J., reported worldwide net revenue of $90.5 million for the second quarter, a significant drop from the $183.8 million reported for the same period in 2014, which the company attributed to purchasers continuing to hold out for generic versions of anticoagulant Angiomax (bivalirudin).